The European Union has approved the Kisunla medication for the treatment of Alzheimer's disease, imposing strict conditions regarding its administration.

The European Commission has approved Kisunla, a treatment for mild cognitive impairments, including dementia in the early stages of Alzheimer's disease. Although the drug, based on the molecule donanemab, has shown promising results in clinical trials, controversy remains regarding its actual benefits and the risks of serious side effects. The authorization is conditional on its administration only to patients without genetic mutations that could increase the risks. EU member states have the freedom to decide on reimbursement, and other countries, such as the United Kingdom, have adopted a similar approach.